

SEP 10 2002

PATENT & TRADEMARK OFFICE

Page 1 of 3

FORM PTO-1449

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1581.0580000/RWE/BECAPPLICATION NO.
09/529,130APPLICANTS
DUGGAN *et al.*§ 371 DATE
June 22, 2000GROUP
1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
CHK	AT	Z	Black, J.D., and Dolly, J.O., "Interaction of ¹²⁵ I-labeled Botulinum Neurotoxins with Nerve Terminals. I. Ultrastructural Autoradiographic Localization and Quantitation of Distinct Membrane Acceptors for Types A and B on Motor Nerves," <i>J. Cell Biol.</i> 103:521-534, The Rockefeller University Press (1986)

RECEIVED

SEP 16 2002

TECH CENTER 1600/2900


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

::ODM\PHD\MA\SKGF_DC1:53805:1

SKGF Rev. 1/95



FORM PTO-1449

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1581.0580000/RWE/BECAPPLICATION NO.
09/529,130APPLICANTS
DUGGAN *et al.*§ 371 DATE
June 22, 2000GROUP
1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CMK	AR	8	Blaustein, R.O., <i>et al.</i> , "The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers," <i>FEBS Letts.</i> 226:115-120, Elsevier Science Publishers B.V. (1987)
	AS	8	Shone, C.C., <i>et al.</i> , "Inactivation of <i>Clostridium botulinum</i> type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity," <i>Eur. J. Biochem.</i> 151:75-82, Springer International (1985)
CMK	AT	8	Shone, C.C., <i>et al.</i> , "A 50-kDa fragment from the NH ₂ -terminus of the heavy subunit of <i>Clostridium botulinum</i> type A neurotoxin forms channels in lipid vesicles," <i>Eur. J. Biochem.</i> 167:175-180, Springer International (1987)

EXAMINER

DATE CONSIDERED

11/18/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SEP 10 2002

Page 3 of 3

FORM PTO-1449

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1581.0580000/RWE/BECAPPLICATION NO.
09/529,130APPLICANTS
DUGGAN *et al.*§ 371 DATE
June 22, 2000GROUP
1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CMK	AR	2	Sutton, J.M., <i>et al.</i> , "Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurones," <i>FEBS Letts.</i> 493:45-49, Elsevier Science B.V. (March 2001)
CMK	AS	2	Yamazaki, N., <i>et al.</i> , "Endogenous lectins as targets for drug delivery," <i>Advanced Drug Delivery Reviews</i> 43:225-244, Elsevier Science B.V. (September 2000)
	AT	2	

RECEIVED

SEP 16 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.